TY - JOUR
T1 - Changes in Health-related Quality of Life for Hepatitis C Virus-Infected People Who Inject Drugs While on Opioid Agonist Treatment Following Sustained Virologic Response
AU - Gormley, Mirinda Ann
AU - Akiyama, Matthew J.
AU - Rennert, Lior
AU - Howard, Kerry A.
AU - Norton, Brianna L.
AU - Pericot-Valverde, Irene
AU - Muench, Sam
AU - Heo, Moonseong
AU - Litwin, Alain H.
N1 - Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Background: Although efforts to treat hepatitis C virus (HCV) in people who inject drugs (PWID) yield high rates of sustained virologic response (SVR), the relationship between successful HCV treatment and health-related quality of life (HRQOL) among PWID is poorly understood. We examined HRQOL changes throughout HCV treatment and post-treatment for PWID achieving SVR. Methods: Participants included 141 PWID who achieved SVR following HCV treatment onsite at 3 opioid agonist treatment (OAT) clinics in the Bronx, New York. EQ-5D-3L assesses 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), producing an index of HRQOL ranging from 0 to 1. EQ-5D-3L was measured at baseline; 4, 8, and 12 weeks during treatment; and 12 and 24 weeks post-treatment. Linear mixed effects regression models assessed changes in the mean EQ-5D-3L index over time. Results: Mean EQ-5D-3L index baseline was 0.66 (standard error [SE]=0.02). While over half the population reported no baseline problems with self-care (85.1%), usual activities (56.0%), and mobility (52.5%), at least two-thirds reported problems with pain/discomfort (78.0%) and anxiety/depression (66.0%). Twenty-four weeks post-treatment, proportions reporting pain/discomfort and anxiety/depression decreased by 25.7% and 24.0%, respectively. Mean EQ-5D-3L index significantly improved during treatment (P<.0001), and improvement was sustained following treatment completion, with mean EQ-5D-3L index of 0.77 (SE=0.02) 12 weeks post-SVR. Conclusions: HCV treatment led to sustained improvement in HRQOL for PWID on OAT who achieved SVR. Future research is necessary to determine whether improvements in HRQOL can be sustained beyond 12 weeks post-SVR.
AB - Background: Although efforts to treat hepatitis C virus (HCV) in people who inject drugs (PWID) yield high rates of sustained virologic response (SVR), the relationship between successful HCV treatment and health-related quality of life (HRQOL) among PWID is poorly understood. We examined HRQOL changes throughout HCV treatment and post-treatment for PWID achieving SVR. Methods: Participants included 141 PWID who achieved SVR following HCV treatment onsite at 3 opioid agonist treatment (OAT) clinics in the Bronx, New York. EQ-5D-3L assesses 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), producing an index of HRQOL ranging from 0 to 1. EQ-5D-3L was measured at baseline; 4, 8, and 12 weeks during treatment; and 12 and 24 weeks post-treatment. Linear mixed effects regression models assessed changes in the mean EQ-5D-3L index over time. Results: Mean EQ-5D-3L index baseline was 0.66 (standard error [SE]=0.02). While over half the population reported no baseline problems with self-care (85.1%), usual activities (56.0%), and mobility (52.5%), at least two-thirds reported problems with pain/discomfort (78.0%) and anxiety/depression (66.0%). Twenty-four weeks post-treatment, proportions reporting pain/discomfort and anxiety/depression decreased by 25.7% and 24.0%, respectively. Mean EQ-5D-3L index significantly improved during treatment (P<.0001), and improvement was sustained following treatment completion, with mean EQ-5D-3L index of 0.77 (SE=0.02) 12 weeks post-SVR. Conclusions: HCV treatment led to sustained improvement in HRQOL for PWID on OAT who achieved SVR. Future research is necessary to determine whether improvements in HRQOL can be sustained beyond 12 weeks post-SVR.
KW - direct-acting antiviral
KW - health-related quality of life
KW - hepatitis C virus
KW - opioid agonist treatment
KW - people who inject drugs
UR - http://www.scopus.com/inward/record.url?scp=85129997412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129997412&partnerID=8YFLogxK
U2 - 10.1093/cid/ciab669
DO - 10.1093/cid/ciab669
M3 - Article
C2 - 34331539
AN - SCOPUS:85129997412
SN - 1058-4838
VL - 74
SP - 1586
EP - 1593
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 9
ER -